Study Stopped
Due to poor enrollment, this study was withdrawn/ terminated.
A Study To Evaluate The Efficacy And Safety Of Betahistine Mesilate In The Treatment Of Patients With Vertigo Caused By Cerebral Infarction In Posterior Circulation
A Multicenter, Placebo-Controlled, Double-Blind Study To Evaluate The Efficacy And Safety Of Betahistine Mesilate In The Treatment Of Patients With Vertigo Caused By Cerebral Infarction In Posterior Circulation
1 other identifier
interventional
N/A
1 country
4
Brief Summary
The purpose of this study is to determine the efficacy and safety of Betahistine Mesilate in the treatment of patients with vertigo caused by Cerebral Infarction in posterior circulation.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
4 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 1, 2007
CompletedFirst Submitted
Initial submission to the registry
May 3, 2007
CompletedFirst Posted
Study publicly available on registry
May 16, 2007
CompletedJune 5, 2017
May 1, 2017
May 3, 2007
June 1, 2017
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Changes in the European Evaluation of Vertigo (EEV) scale in 4 weeks.
4 weeks
Secondary Outcomes (1)
The duration of the vertigo symptom.
Interventions
Eligibility Criteria
You may qualify if:
- \. Patients that have a clinical diagnosis of posterior circulation infarction and vertigo occurring within 1 month after the infarction.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Eisai Inc.lead
Study Sites (4)
Beijing Tiantan Hospital
Beijing, Beijing Municipality, 100050, China
Beijing Hospital
Beijing, Beijing Municipality, 100730, China
Shanghai Renji Hospital
Shanghai, Shanghai Municipality, 20001, China
Shanghai Huashan Hospital
Shanghai, Shanghai Municipality, 200040, China
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Wang Yong Jun
Beijing Tiantan Hospital
Study Design
- Study Type
- interventional
- Phase
- phase 4
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, INVESTIGATOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 3, 2007
First Posted
May 16, 2007
Study Start
May 1, 2007
Last Updated
June 5, 2017
Record last verified: 2017-05